Did Ginkgo Bioworks Fall Catch You Out? What Investors Missed

If you had backed the bullish October 2025 case that Ginkgo Bioworks could tighten costs, scale automation and earn a premium P/E, the past year would feel rough. Holding Ginkgo Bioworks over the past year would have meant a 26.4% loss, including dividends. If that decision hinged on revenue shrinking mid single digits, margins moving toward 14.2% and a near 40x to 48x P/E in 2028, which of those specific levers did the original thesis underweight?

Ginkgo Bioworks is not the only name tied to this theme. Zero in on 38 AI small caps and compare how each one is priced.

The Argument You Would Have Been Weighing Up On Ginkgo Bioworks

The shares cost US$13.21 at the start of the period, so any view on Ginkgo Bioworks really came down to which story about automation and AI you trusted more.

On the bullish side, the narrative pointed to a Fair Value of US$16, a price implied by assumptions that revenue would decline 6.5% a year yet profit margin would climb toward 14.2% and support a future P/E of 48.2x.

The more cautious thesis saw Fair Value at US$11.33, with expectations that annual revenue would fall 10.2% while any eventual 14.2% profit margin and 38.5x assumed P/E faced slower sector adoption and underused lab space risk.

What The Results Changed For The Ginkgo Bioworks Thesis

Ginkgo Bioworks gave NSF X-Labs researchers access to its autonomous Nebula lab and expanded imaging capability with Araceli, which supported parts of the bullish automation story. The numbers told a harder truth. Revenue declined from US$39.134m in Q2 2025 to US$20.156m in Q2 2026, while the company reported a larger net loss and net margin moved further away from the 14.2% profit assumption.

The lesson is simple. When a pitch leans on future margin repair, treat reported net margin as the key test and track whether each set of results actually closes that gap.

What Today's Ginkgo Bioworks Price Already Reflects

Today Ginkgo Bioworks trades at US$9.99, after a 26.4% loss over the past year. The selected Narrative sets its Fair Value below the current price, framed around concerns that expectations for automation, AI tools and sector funding may be running ahead of near term commercial traction.

That same Narrative also highlights balance sheet strength, cost actions and lab automation progress as potential long run positives. Any buyer at today’s level would need to judge how quickly underused lab capacity, AI monetization and revenue execution can improve before a lower entry point looks like a clearer opportunity.

"Investors may be overestimating the speed and magnitude by which Ginkgo's expansion into life science tools and automated lab systems will convert into sustainable revenue growth, given the company's reliance on adoption of novel general-purpose automation platforms in a historically slow-moving, risk-averse sector, potentially leading to overoptimistic revenue projections over the next several years."

One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all

Another Way To Play Lab Demand?

If Ginkgo Bioworks keeps leaning into automation, attention can shift to who turns those biological insights into treatments and procedures.

Drug developers and device makers still face a blunt need to refresh product portfolios and keep new therapies moving through approvals.

One large healthcare group is spending heavily on research, acquisitions and late stage programs to meet that demand.

Its therapies reach serious disease areas and complex procedures, where treatment options and surgical tools influence how doctors work every day.

If that pipeline keeps producing usable products, the long term role this business plays in healthcare could end up looking very different from today.

It is written up in full, assumptions and all. → Explore the Narrative that puts this company 21% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com